Interim clinical commissioning policy statement: Teriparatide for osteoporosis in men (adults)

Document first published:
Page updated:
Publication type:

The current commissioning arrangements for treatment of osteoporosis do not include a mechanism by which men with the most severe forms of osteoporosis can access teriparatide. Teriparatide is the most effective available treatment for this patient group.


Based on a limited scoping of the evidence, NHS England has concluded that there is sufficient evidence to support interim commissioning of this treatment for the indications and clinical criteria listed in this statement in adults.